marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2024
added 02-27-2025
Crinetics Pharmaceuticals Financial Ratios 2011-2025 | CRNX
Annual Financial Ratios Crinetics Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-9.1 | -11.5 | -6.2 | -10.1 | -5.8 | -10.6 | -11.1 | - | - | - | - | - | - | - |
P/S |
2601.5 | 613.7 | 216.0 | 1013.0 | 6051.0 | 448.2 | 123.7 | - | - | - | - | - | - | - |
EPS |
-3.7 | -3.7 | -3.1 | -2.8 | -2.4 | -2.1 | -2.2 | -6.7 | -6.0 | - | - | - | - | - |
EV (Enterprise Value) |
2.55 B | 2.5 B | 1.03 B | 910 M | 351 M | 508 M | 267 M | 16.4 M | 6.65 M | - | - | - | - | - |
EBITDA per Share |
-4.16 | -3.81 | -3.21 | -2.78 | -2.43 | -2.19 | -2.33 | - | - | - | - | - | - | - |
EV/EBITDA |
-8.4 | -4754.7 | -9.3 | -9.0 | - | - | - | - | - | - | - | |||
PEG |
- | -59.26 | -1.69 | 0.12 | - | - | - | - | - | - | - | |||
P/B |
2.0 | 4.6 | 3.2 | 3.3 | 2.5 | 4.6 | 1.9 | - | - | - | - | - | - | - |
P/CF |
-12.0 | -14.8 | -8.9 | -12.3 | -6.9 | -11.4 | -14.6 | - | - | - | - | - | - | - |
ROE % |
-22.52 | -39.79 | -51.82 | -32.43 | -43.70 | -43.04 | -16.92 | - | - | - | - | - | - | - |
ROA % |
-20.80 | -33.77 | -46.54 | -30.67 | -40.24 | -38.67 | -15.82 | - | - | - | - | - | - | - |
ROCE % |
-25.58 | -41.29 | -53.07 | -32.45 | -44.37 | -44.11 | -17.56 | - | - | - | - | - | - | - |
Current Ratio |
13.1 | 6.6 | 9.8 | 18.4 | 12.6 | 14.8 | 21.0 | - | - | - | - | - | - | - |
DSO |
2002.4 | 204.6 | 53.9 | - | - | 421.6 | 238.1 | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
2002.4 | 204.7 | 53.9 | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
2002.4 | 204.7 | 53.9 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Crinetics Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.96 | -0.94 | -0.93 | - | -1.01 | -0.94 | -0.85 | - | -0.78 | -0.81 | -0.73 | - | -0.73 | -0.7 | -0.69 | - | -0.56 | -0.53 | -0.71 | -0.6 | -0.6 | -0.51 | -0.37 | -0.35 | -0.38 | -2.41 | -2.92 | -1.68 | -1.67 | -1.22 | -2.18 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | -1.01 | - | - | - | -0.88 | - | -0.8 | -0.81 | -0.7 | - | -0.71 | -0.69 | -0.69 | - | -0.54 | -0.52 | -0.72 | - | -0.6 | -0.53 | -0.41 | - | -0.39 | -2.41 | -2.93 | - | -1.6 | -1.18 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-36.28 | -37.54 | -48.69 | -46.96 | -58.89 | -60.33 | -51.24 | -34.33 | -48.72 | -51.17 | -53.15 | -42.66 | -53.51 | -49.97 | -46.77 | -30.89 | -43.31 | -44.78 | -45.62 | -43.04 | -35.93 | -28.34 | -21.21 | -16.92 | 5.16 | 25.75 | 40.20 | 43.61 | 26.83 | 10.97 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-31.91 | -32.67 | -42.14 | -40.99 | -51.88 | -53.82 | -46.48 | -31.33 | -44.63 | -47.04 | -49.02 | -39.33 | -49.32 | -46.01 | -42.97 | -28.44 | -39.60 | -40.68 | -41.22 | -38.67 | -32.47 | -25.83 | -19.55 | -15.82 | -27.02 | -37.87 | -45.19 | -42.00 | -25.84 | -10.57 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-39.68 | -39.90 | -50.79 | -48.74 | -61.10 | -62.70 | -53.00 | -34.68 | -49.04 | -51.04 | -52.84 | -42.65 | -53.57 | -50.13 | -47.20 | -31.47 | -44.47 | -46.55 | -47.92 | -32.97 | -38.00 | -30.04 | -22.19 | -12.03 | 3.77 | 24.61 | 39.10 | 26.74 | 26.74 | 10.94 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
9.0 | 8.9 | 9.5 | 6.6 | 6.8 | 7.5 | 9.3 | 9.8 | 11.5 | 11.9 | 11.0 | 18.4 | 13.3 | 14.0 | 11.6 | 12.6 | 12.6 | 12.6 | 12.6 | 9.8 | 9.8 | 9.8 | 9.8 | 15.3 | 15.3 | 15.3 | 15.3 | 16.9 | 16.9 | 16.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency